Epicrispr’s $90m round bets big on epigenetics
Oversubscribed Series C pushes EPI-321 toward pivotal trials, testing whether “silencing genes without editing them” can become real therapy. Epicrispr Biotechnologies has closed a $90 million Series C financing round, and the syndicate behind it reads like a checklist of biotech credibility: Octago
<p>Oversubscribed Series C pushes EPI-321 toward pivotal trials, testing whether “silencing genes without editing them” can become real therapy. Epicrispr Biotechnologies has closed a $90 million Series C financing round, and the syndicate behind it reads like a checklist of biotech credibility: Octago</p>